Subscribe

Janux Therapeutics, Inc. (JANX)

USD15.88 +0.10 (+0.66%)
US NASDAQ Healthcare Biotechnology
Address 11099 North Torrey Pines Road 92037
San Diego, CA, US
CEO David Alan Campbell
Website januxrx.com
IPO 2021-06-11
CIK 1817713 ISIN US47103J1051

Explore sections of this company profile

Description

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD15.88 +0.10 (+0.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.51
Float Shares
55.73M
Free Float %
91.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.26% -1.30% -3.48% +9.75% -49.47% +4.42% -44.70% +13.02% -42.70% -42.70% -42.70%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (15 ratings, all time) Buy
Price Targets & DCF
Current price
15.88
Low 14.00 -11.9%
Consensus 28.57 +79.9%
Median 30.00 +88.9%
High 45.00 +183.3%
Ratings Trend (MoM) 83% Bullish
Rating 2026-05 Change
Strong Buy 2 -1
Buy 13 -1
Hold 2 0
Sell 0 0
Strong Sell 1 0
Price Target Summary
Period # Analysts Avg Target
Last Month 3
21.67
+36.4%
Last Quarter 3
21.67
+36.4%
Last Year 12
41.08
+158.6%
All Time 21
50.62
+218.7%
Quality scores
Altman Z-Score
6.18
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -5.6%
  • ✗
    EPS growth Biotechnology: +29.7%
    -43.0% Q1'26: -2.6% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -1,059.3% Q1'26: -337.8% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -1,136.3% Q1'26: -916.5% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -916.8% Q1'26: -2,036.5% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +15.3% Q1'26: +1.4% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.20× Q1'26: -0.16× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (2.57) × ERP
WACC = 98% × Ke + 2% × Kd (4.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 15.88
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
8 Rev. Ana.
12 EPS Ana. 		Dec 2027
9 Rev. Ana.
12 EPS Ana. 		Dec 2028
12 Rev. Ana.
12 EPS Ana. 		Dec 2029
11 Rev. Ana.
10 EPS Ana. 		Dec 2030
6 Rev. Ana.
5 EPS Ana.
Revenue
3.64M
est: 2.45M (+48.6%)
8.61M
est: 6.58M (+31.0%)
8.08M
est: 15.13M (-46.6%)
10.59M
est: 10.99M (-3.7%)
10.00M
est: 10.06M (-0.6%)
29.66M
27.59M – 31.73M
+194.8% YoY
7.52M
5.14M – 9.31M
-74.7% YoY
18.55M
12.69M – 22.99M
+146.8% YoY
81.15M
55.52M – 100.56M
+337.4% YoY
151.48M
103.64M – 187.72M
+86.7% YoY
EBITDA
-32.82M
est: -1.47M (-2,134.8%)
-66.25M
est: -3.95M (-1,579.3%)
-71.02M
est: -15.13M (-369.5%)
-96.79M
est: -10.99M (-780.4%)
-111.60M
est: -10.06M (-1,009.0%)
-29.66M
-31.73M – -27.59M
-194.8% YoY
-7.52M
-9.31M – -5.14M
+74.7% YoY
-18.55M
-22.99M – -12.69M
-146.8% YoY
-81.15M
-100.56M – -55.52M
-337.4% YoY
-151.48M
-187.72M – -103.64M
-86.7% YoY
EBIT
-32.93M
est: -1.47M (-2,142.5%)
-67.09M
est: -3.95M (-1,600.7%)
-72.98M
est: -15.13M (-382.4%)
-98.85M
est: -10.99M (-799.2%)
-113.63M
est: -10.06M (-1,029.2%)
-29.66M
-31.73M – -27.59M
-194.8% YoY
-7.52M
-9.31M – -5.14M
+74.7% YoY
-18.55M
-22.99M – -12.69M
-146.8% YoY
-81.15M
-100.56M – -55.52M
-337.4% YoY
-151.48M
-187.72M – -103.64M
-86.7% YoY
Net Income
-32.67M
est: -67.05M (+51.3%)
-63.06M
est: -91.26M (+30.9%)
-58.29M
est: -44.05M (-32.3%)
-68.99M
est: -105.64M (+34.7%)
-113.63M
est: -127.41M (+10.8%)
-143.20M
-151.29M – -91.78M
-12.4% YoY
-209.01M
-217.99M – -132.20M
-46.0% YoY
-269.02M
-305.05M – -137.73M
-28.7% YoY
-234.36M
-307.23M – -138.13M
+12.9% YoY
-192.17M
-251.92M – -113.26M
+18.0% YoY
SGA
10.33M
est: 6.63M (+55.9%)
22.26M
est: 17.80M (+25.1%)
26.14M
est: 50.56M (-48.3%)
41.05M
est: 36.75M (+11.7%)
41.77M
est: 33.63M (+24.2%)
99.14M
92.23M – 106.06M
+194.8% YoY
25.12M
17.19M – 31.13M
-74.7% YoY
62.01M
42.42M – 76.84M
+146.8% YoY
271.24M
185.57M – 336.11M
+337.4% YoY
506.34M
346.41M – 627.45M
+86.7% YoY
EPS
-0.79
est: -1.25 (+36.7%)
-1.52
est: -1.65 (+7.6%)
-1.32
est: -0.90 (-46.8%)
-1.28
est: -1.46 (+12.4%)
-1.83
est: -1.98 (+7.4%)
-1.92
-2.44 – -1.48
+2.8% YoY
-2.80
-3.52 – -2.13
-46.0% YoY
-3.49
-4.92 – -2.22
-24.4% YoY
-3.78
-4.96 – -2.23
-8.4% YoY
-3.10
-4.07 – -1.83
+18.0% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-05-08 Guggenheim Buy Buy Maintain
2026-04-28 Jones Trading Buy Buy Maintain
2026-04-20 Barclays Overweight Underweight Downgrade
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-07 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-06 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-05 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-04 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-01 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-04-30 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-04-29 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-04-28 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-04-27 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-04-24 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-23 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-22 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-21 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-20 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-17 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-16 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-98.42M
OE per share TTM
-1.58
Owner's Yield
-11.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
258.0%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
62
Total invested
73.53M
Insider transactions (90d)
0
Beneficial owners (>5%)
50
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 Jay Lichter, Ph.D. (“Lichter”) 8.90M 21.40% 30.0K 8.87M 30.0K 8.87M IN — 2021-06-25 ↗
2 Peter Kolchinsky 8.67M 20.80% — 8.67M — 10.00 HC, IN United States 2021-06-16 ↗
3 RA Capital Management, L.P. 8.67M 20.80% — 8.67M — 10.00 IA, PN Delaware 2021-06-16 ↗
4 Rajeev Shah 8.67M 20.80% — 8.67M — 10.00 HC, IN United States 2021-06-16 ↗
5 RA Capital Healthcare Fund, L.P. 7.62M 18.30% — 7.62M — 10.00 PN Delaware 2021-06-16 ↗
6 Abigail P. Johnson 4.99M 12.00% — — 4.99M — IN Delaware 2022-01-10 ↗
7 FMR LLC 4.99M 12.00% 640.0K — 4.99M — HC Delaware 2022-01-10 ↗
8 Tighe Reardon (“Reardon”) 4.84M 11.60% 365.1K 4.48M 365.1K 4.48M IN — 2021-06-25 ↗
9 ABV SPV I GP LLC (“ABV GP”) 4.48M 10.80% — 4.48M — 4.48M OO — 2021-06-25 ↗
10 Avalon BioVentures SPV I, L.P. (“ABV SPV”) 4.48M 10.76% — 4.48M — 4.48M PN — 2021-06-25 ↗
11 Avalon Ventures XI GP LLC (“Avalon XI GP”) 4.39M 10.50% — 4.39M — 4.39M OO — 2021-06-25 ↗
12 Avalon Ventures XI, L.P. (“Avalon Ventures”) 4.39M 10.50% — 4.39M — 4.39M PN — 2021-06-25 ↗
13 Braden Bohrmann (“Bohrmann”) 4.39M 10.50% — 4.39M — 4.39M IN — 2021-06-25 ↗
14 Kevin Kinsella (“Kinsella”) 4.39M 10.50% — 4.39M — 4.39M IN — 2021-06-25 ↗
15 Richard Levandov (“Levandov”) 4.39M 10.50% — 4.39M — 4.39M IN — 2021-06-25 ↗
16 BVF Inc. 4.11M 9.80% — — — 4.11M CO Delaware 2023-05-30 ↗
17 BVF Partners L.P. 4.11M 9.80% — — — 4.11M IA, PN Delaware 2023-05-30 ↗
18 Mark N. Lampert 4.11M 9.80% — — — 4.11M IN Delaware 2023-05-30 ↗
19 BVF GP Holdings LLC 3.85M 9.20% — — — 3.85M OO Delaware 2023-05-30 ↗
20 of 5 Pages 3.75M 9.00% 3.75M — 3.75M — CO British Virgin Islands 2021-06-25 ↗
21 EcoR1 Capital, LLC 3.26M 11.00% — 3.26M — 3.26M IA, OO Delaware 2023-01-23 ↗
22 Oleg Nodelman 3.26M 11.00% — 3.26M — 3.26M HC, IN Delaware 2023-01-23 ↗
23 OrbiMed Advisors LLC 3.04M 7.30% — 3.04M — 10.00 IA Delaware 2021-06-22 ↗
24 EcoR1 Capital Fund Qualified, L.P. 3.03M 11.00% — 3.03M — 3.03M PN Delaware 2023-01-23 ↗
25 OrbiMed Capital GP VIII LLC 2.76M 6.60% — 2.76M — 10.00 OO Delaware 2021-06-22 ↗
26 Paradigm BioCapital Advisors LP 2.61M 5.00% 2.61M — 2.61M — PN Delaware 2024-10-23 ↗
27 EIN #00-0000000 2.40M 5.80% — 2.40M — 2.40M IA, HC Jersey, Channel Islands 2022-02-14 ↗
28 David Campbell, Ph.D. 2.28M 5.50% 2.28M — 2.28M — IN United States 2022-02-11 ↗
29 BVF I GP LLC 2.18M 5.20% — — — 2.18M OO Delaware 2023-05-30 ↗
30 Biotechnology Value Fund, L.P. 2.18M 5.20% — — — 2.18M PN Delaware 2023-05-30 ↗
31 Jay Lichter, Ph.D. 2.15M 4.10% 97.7K 2.05M 97.7K 11.00 IN — 2024-11-08 ↗
32 BVF II GP LLC 1.67M 4.00% — — — 1.67M OO Delaware 2023-05-30 ↗
33 Biotechnology Value Fund II, L.P. 1.67M 4.00% — — — 1.67M PN Delaware 2023-05-30 ↗
34 Tighe Reardon 1.59M 3.00% 470.5K 1.12M 470.5K 11.00 IN — 2024-11-08 ↗
35 Richard Levandov 978.6K 1.90% 53.6K 925.1K 53.6K 11.00 IN — 2024-11-08 ↗
36 Kevin Kinsella 975.0K 1.90% 49.9K 925.1K 49.9K 11.00 IN — 2024-11-08 ↗
37 Braden Bohrmann 962.3K 1.80% 37.2K 925.1K 37.2K 11.00 IN — 2024-11-08 ↗
38 ABV SPV I GP LLC 944.5K 1.80% — 944.5K — 11.00 OO — 2024-11-08 ↗
39 Avalon BioVentures SPV I, L.P. 944.5K 1.80% — 944.5K — 11.00 PN — 2024-11-08 ↗
40 Avalon Ventures XI GP LLC 925.1K 1.80% — 925.1K — 11.00 OO — 2024-11-08 ↗
41 Avalon Ventures XI, L.P. 925.1K 1.80% — 925.1K — 11.00 PN — 2024-11-08 ↗
42 OrbiMed Capital LLC 423.6K 1.00% 423.6K — 423.6K 10.00 OO Cayman Islands 2021-06-22 ↗
43 OrbiMed Genesis GP LLC 282.4K 0.70% — 282.4K — 10.00 IA Cayman Islands 2021-06-22 ↗
44 Sanford Madigan, Ph.D. 234.5K 0.40% 55.3K 179.2K 55.3K 11.00 IN — 2024-11-08 ↗
45 Sergio G. Duron, Ph.D. 224.6K 0.40% 45.4K 179.2K 45.4K 11.00 IN — 2024-11-08 ↗
46 BVF Partners OS Ltd. 209.5K 1.00% — — — 209.5K CO Delaware 2023-05-30 ↗
47 Biotechnology Value Trading Fund OS LP 209.5K 1.00% — — — 209.5K PN Delaware 2023-05-30 ↗
48 Avalon BioVentures GP, LLC 179.2K 0.30% — 179.2K — 11.00 OO — 2024-11-08 ↗
49 Avalon BioVentures I, LP 179.2K 0.30% — 179.2K — 11.00 PN — 2024-11-08 ↗
50 Citadel Advisors Holdings LP 6.00 4.90% — 2.03M — — HC, PN Delaware 2023-07-10 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
62
-126 vs prev Q
New positions
25
Closed positions
139
Increased
41
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 MACQUARIE MANAGEMENT HOLDINGS, INC. 76.6K +76.6K (+100.0%) 1.06B +1.1B (+100.0%) 0.12% +0.124 pp 0.00% +0.002 pp USD13.80 +0.0% 1 qtrs NEW
2 RA CAPITAL MANAGEMENT, L.P. 11.19M +— (+0.0%) 154.42M -119.1M (-43.5%) 18.04% -0.035 pp 1.58% -1.788 pp USD27.51 -49.8% 19 qtrs —
3 JANUS HENDERSON GROUP PLC 5.35M +649.3K (+13.8%) 73.85M -41.1M (-35.8%) 8.63% +1.032 pp 0.03% -0.019 pp USD31.56 -56.3% 19 qtrs —
4 BLACKROCK, INC. 4.08M +349.2K (+9.4%) 56.31M -34.9M (-38.3%) 6.58% +0.551 pp 0.00% -0.001 pp USD38.07 -63.8% 6 qtrs —
5 STATE STREET CORP 3.85M +2.0M (+103.8%) 53.18M +7.0M (+15.0%) 6.21% +3.158 pp 0.00% +0.000 pp USD22.77 -39.4% 18 qtrs —
6 FMR LLC 3.51M -5.5M (-61.2%) 48.47M -172.9M (-78.1%) 5.66% -8.967 pp 0.00% -0.009 pp USD28.81 -52.1% 19 qtrs —
7 VANGUARD GROUP INC 2.91M +489.3K (+20.2%) 40.11M -19.0M (-32.1%) 4.69% +0.781 pp 0.00% 0.000 pp USD27.97 -50.7% 19 qtrs —
8 PROSIGHT MANAGEMENT, LP 2.39M +1.5M (+176.5%) 33.02M +11.9M (+56.1%) 3.86% +2.460 pp 6.82% +1.890 pp USD21.26 -35.1% 6 qtrs —
9 ORBIMED ADVISORS LLC 1.95M +188.3K (+10.7%) 26.97M -16.2M (-37.5%) 3.15% +0.298 pp 0.55% -0.465 pp USD23.76 -41.9% 19 qtrs —
10 TCG CROSSOVER MANAGEMENT, LLC 1.79M +1.8M (+100.0%) 24.70M +24.7M (+100.0%) 2.89% +2.885 pp 0.82% +0.817 pp USD13.80 +0.0% 1 qtrs NEW
11 WELLINGTON MANAGEMENT GROUP LLP 1.61M +908.6K (+129.5%) 22.22M +5.1M (+29.6%) 2.60% +1.463 pp 0.00% +0.001 pp USD25.37 -45.6% 8 qtrs —
12 ALYESKA INVESTMENT GROUP, L.P. 1.30M +876.2K (+206.3%) 17.96M +7.6M (+72.9%) 2.10% +1.411 pp 0.05% +0.019 pp USD18.11 -23.8% 10 qtrs —
13 GEODE CAPITAL MANAGEMENT, LLC 1.11M +29.7K (+2.7%) 15.37M -11.1M (-42.0%) 1.80% +0.045 pp 0.00% -0.001 pp USD26.94 -48.8% 19 qtrs —
14 CITADEL ADVISORS LLC 1.10M +301.4K (+37.5%) 15.24M -4.4M (-22.3%) 1.78% +0.483 pp 0.00% -0.001 pp USD22.33 -38.2% 19 qtrs —
15 GOLDMAN SACHS GROUP INC 1.07M +418.5K (+63.9%) 14.82M -1.2M (-7.5%) 1.73% +0.673 pp 0.00% 0.000 pp USD23.79 -42.0% 19 qtrs —
16 WOODLINE PARTNERS LP 1.03M +283.0 (+0.0%) 14.18M -10.9M (-43.5%) 1.66% -0.003 pp 0.05% -0.063 pp USD45.86 -69.9% 19 qtrs —
17 LOGOS GLOBAL MANAGEMENT LP 1.00M +65.0K (+7.0%) 13.80M -9.1M (-39.6%) 1.61% +0.102 pp 0.83% -1.214 pp USD38.43 -64.1% 8 qtrs —
18 POINT72 ASSET MANAGEMENT, L.P. 961.8K -748.4K (-43.8%) 13.27M -28.5M (-68.2%) 1.55% -1.212 pp 0.01% -0.055 pp USD27.40 -49.6% 7 qtrs —
19 READYSTATE ASSET MANAGEMENT LP 885.9K -74.5K (-7.8%) 12.23M -11.2M (-47.9%) 1.43% -0.123 pp 0.50% -0.505 pp USD32.01 -56.9% 6 qtrs —
20 BALYASNY ASSET MANAGEMENT L.P. 885.6K +885.6K (+100.0%) 12.22M +12.2M (+100.0%) 1.43% +1.428 pp 0.02% +0.016 pp USD13.80 +0.0% 3 qtrs —
21 PRICE T ROWE ASSOCIATES INC /MD/ 744.5K -521.1K (-41.2%) 10.27M -20.7M (-66.8%) 1.20% -0.844 pp 0.00% -0.002 pp USD41.48 -66.7% 8 qtrs —
22 BANK OF AMERICA CORP /DE/ 738.3K +244.9K (+49.6%) 10.19M -1.9M (-15.5%) 1.19% +0.393 pp 0.00% 0.000 pp USD36.94 -62.6% 19 qtrs —
23 CORMORANT ASSET MANAGEMENT, LP 650.0K -200.0K (-23.5%) 8.97M -11.8M (-56.8%) 1.05% -0.325 pp 0.41% -1.019 pp USD46.19 -70.1% 8 qtrs —
24 MORGAN STANLEY 618.4K +122.8K (+24.8%) 8.53M -3.6M (-29.6%) 1.00% +0.196 pp 0.00% 0.000 pp USD27.97 -50.7% 19 qtrs —
25 UBS GROUP AG 590.1K +199.7K (+51.2%) 8.14M -1.4M (-14.6%) 0.95% +0.321 pp 0.00% 0.000 pp USD27.44 -49.7% 8 qtrs —
26 JANE STREET GROUP, LLC 540.2K +458.9K (+564.3%) 7.46M +5.5M (+275.1%) 0.87% +0.740 pp 0.00% +0.001 pp USD15.32 -9.9% 8 qtrs —
27 TWO SIGMA INVESTMENTS, LP 471.0K +367.5K (+355.2%) 6.50M +4.0M (+157.0%) 0.76% +0.592 pp 0.01% +0.005 pp USD15.84 -12.9% 10 qtrs —
28 ADAGE CAPITAL PARTNERS GP, L.L.C. 400.0K -2.4M (-85.6%) 5.52M -62.3M (-91.9%) 0.64% -3.838 pp 0.01% -0.099 pp USD33.23 -58.5% 19 qtrs —
29 SQUAREPOINT OPS LLC 391.0K +324.8K (+490.9%) 5.40M +3.8M (+233.7%) 0.63% +0.523 pp 0.01% +0.004 pp USD15.94 -13.4% 12 qtrs —
30 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 390.5K +36.0K (+10.1%) 5.39M -3.3M (-37.8%) 0.63% +0.057 pp 0.00% -0.001 pp USD35.36 -61.0% 18 qtrs —
31 FRANKLIN RESOURCES INC 385.3K -502.5K (-56.6%) 5.32M -16.4M (-75.5%) 0.62% -0.813 pp 0.00% -0.004 pp USD37.96 -63.6% 7 qtrs —
32 NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. 376.5K +— (+0.0%) 5.20M -4.0M (-43.5%) 0.61% -0.001 pp 0.46% -0.250 pp USD45.43 -69.6% 6 qtrs —
33 UNIVERSITY OF WISCONSIN FOUNDATION 362.0K +362.0K (+100.0%) 5.00M +5.0M (+100.0%) 0.58% +0.584 pp 4.20% +4.200 pp USD13.80 +0.0% 1 qtrs NEW
34 ROCK SPRINGS CAPITAL MANAGEMENT LP 358.8K +148.4K (+70.6%) 4.95M -189.9K (-3.7%) 0.58% +0.239 pp 0.25% -0.047 pp USD36.60 -62.3% 5 qtrs —
35 NORTHERN TRUST CORP 340.4K -13.7K (-3.9%) 4.70M -4.0M (-45.7%) 0.55% -0.023 pp 0.00% -0.001 pp USD28.01 -50.7% 18 qtrs —
36 WALLEYE CAPITAL LLC 323.0K +287.2K (+801.8%) 4.46M +3.6M (+409.2%) 0.52% +0.463 pp 0.01% +0.010 pp USD14.92 -7.5% 4 qtrs —
37 SUSQUEHANNA INTERNATIONAL GROUP, LLP 300.5K +133.4K (+79.8%) 4.15M +63.0K (+1.5%) 0.48% +0.215 pp 0.00% +0.000 pp USD26.18 -47.3% 8 qtrs —
38 MILLENNIUM MANAGEMENT LLC 289.8K +189.2K (+188.0%) 4.00M +1.5M (+62.6%) 0.47% +0.305 pp 0.00% +0.001 pp USD21.09 -34.6% 5 qtrs —
39 CAPTION MANAGEMENT, LLC 272.5K +182.5K (+202.8%) 3.76M +1.6M (+71.0%) 0.44% +0.294 pp 0.03% +0.009 pp USD17.85 -22.7% 5 qtrs —
40 PICTET ASSET MANAGEMENT HOLDING SA 272.3K -322.6K (-54.2%) 3.76M -10.8M (-74.2%) 0.44% -0.522 pp 0.00% -0.010 pp USD42.12 -67.2% 5 qtrs —
41 SCHRODER INVESTMENT MANAGEMENT GROUP 267.1K -31.8K (-10.6%) 3.69M -3.4M (-47.9%) 0.43% -0.052 pp 0.00% -0.003 pp USD37.32 -63.0% 7 qtrs —
42 ADAR1 CAPITAL MANAGEMENT, LLC 245.5K -105.6K (-30.1%) 3.39M -5.2M (-60.5%) 0.40% -0.171 pp 0.25% -0.557 pp USD25.66 -46.2% 8 qtrs —
43 RHENMAN & PARTNERS ASSET MANAGEMENT AB 225.4K +125.3K (+125.1%) 3.11M +663.1K (+27.1%) 0.36% +0.202 pp 0.29% +0.020 pp USD23.22 -40.6% 8 qtrs —
44 DIMENSIONAL FUND ADVISORS LP 224.3K -16.3K (-6.8%) 3.10M -2.8M (-47.4%) 0.36% -0.027 pp 0.00% -0.001 pp USD24.80 -44.4% 8 qtrs —
45 BARCLAYS PLC 221.2K +47.2K (+27.1%) 3.05M -4.9M (-61.4%) 0.36% +0.076 pp 0.00% -0.001 pp USD28.37 -51.4% 16 qtrs —
46 QUBE RESEARCH & TECHNOLOGIES LTD 216.0K +105.2K (+94.9%) 2.98M +271.7K (+10.0%) 0.35% +0.169 pp 0.00% +0.000 pp USD30.88 -55.3% 7 qtrs —
47 ALGERT GLOBAL LLC 183.4K +95.2K (+107.9%) 2.53M +374.0K (+17.3%) 0.30% +0.153 pp 0.04% +0.003 pp USD24.07 -42.7% 6 qtrs —
48 RAFFERTY ASSET MANAGEMENT, LLC 175.2K +99.1K (+130.0%) 2.42M +556.2K (+29.9%) 0.28% +0.160 pp 0.01% +0.002 pp USD22.77 -39.4% 7 qtrs —
49 JPMORGAN CHASE & CO 170.5K -38.7K (-18.5%) 2.35M -2.8M (-54.0%) 0.27% -0.063 pp 0.00% 0.000 pp USD37.72 -63.4% 19 qtrs —
50 TREXQUANT INVESTMENT LP 170.5K +157.3K (+1,189.9%) 2.35M +2.0M (+628.3%) 0.27% +0.254 pp 0.02% +0.018 pp USD15.63 -11.7% 5 qtrs —
51 EXODUSPOINT CAPITAL MANAGEMENT, LP 161.5K +161.5K (+100.0%) 2.23M +2.2M (+100.0%) 0.26% +0.261 pp 0.02% +0.018 pp USD13.80 +0.0% 6 qtrs —
52 XTX TOPCO LTD 161.4K +161.4K (+100.0%) 2.23M +2.2M (+100.0%) 0.26% +0.260 pp 0.06% +0.059 pp USD13.80 +0.0% 1 qtrs NEW
53 SPHERA FUNDS MANAGEMENT LTD. 157.8K +72.0K (+83.9%) 2.18M +80.3K (+3.8%) 0.25% +0.116 pp 0.42% -0.022 pp USD28.82 -52.1% 5 qtrs —
54 DEKABANK DEUTSCHE GIROZENTRALE 49.5K +— (+0.0%) 2.04M +21.0K (+1.0%) 0.08% 0.000 pp 0.00% +0.000 pp USD12.21 +13.0% 17 qtrs —
55 BANK OF NEW YORK MELLON CORP 122.1K +1.6K (+1.3%) 1.68M -1.3M (-42.8%) 0.20% +0.002 pp 0.00% 0.000 pp USD29.08 -52.5% 18 qtrs —
56 HUDSON BAY CAPITAL MANAGEMENT LP 110.0K +60.0K (+120.0%) 1.52M +296.0K (+24.2%) 0.18% +0.097 pp 0.01% +0.001 pp USD20.71 -33.4% 6 qtrs —
57 TWO SIGMA ADVISERS, LP 104.1K +104.1K (+100.0%) 1.44M +1.4M (+100.0%) 0.17% +0.168 pp 0.00% +0.003 pp USD13.80 +0.0% 1 qtrs NEW
58 BLUE OWL CAPITAL HOLDINGS LP 100.0K +100.0K (+100.0%) 1.38M +1.4M (+100.0%) 0.16% +0.161 pp 0.10% +0.103 pp USD13.80 +0.0% 1 qtrs NEW
59 JUMP FINANCIAL, LLC 96.7K -83.0K (-46.2%) 1.33M -3.1M (-69.6%) 0.16% -0.134 pp 0.02% -0.036 pp USD24.71 -44.2% 4 qtrs —
60 NUVEEN, LLC 96.4K +787.0 (+0.8%) 1.33M -1.0M (-43.1%) 0.16% +0.001 pp 0.00% 0.000 pp USD26.89 -48.7% 4 qtrs —
61 DEEP TRACK CAPITAL, LP 89.6K +89.6K (+100.0%) 1.24M +1.2M (+100.0%) 0.14% +0.144 pp 0.02% +0.022 pp USD13.80 +0.0% 1 qtrs NEW
62 SG AMERICAS SECURITIES, LLC 79.8K +50.8K (+175.1%) 1.10M +392.0K (+55.3%) 0.13% +0.082 pp 0.00% -0.001 pp USD17.94 -23.1% 9 qtrs —
63 TUDOR INVESTMENT CORP ET AL 79.2K -19.4K (-19.7%) 1.09M -1.3M (-54.6%) 0.13% -0.032 pp 0.00% -0.002 pp USD27.00 -48.9% 4 qtrs —
64 SWISS NATIONAL BANK 77.1K +2.5K (+3.4%) 1.06M -759.2K (-41.6%) 0.12% +0.004 pp 0.00% 0.000 pp USD34.69 -60.2% 12 qtrs —
65 UBS ASSET MANAGEMENT AMERICAS INC 75.5K +9.2K (+13.8%) 1.04M -579.1K (-35.7%) 0.12% +0.015 pp 0.00% 0.000 pp USD44.53 -69.0% 8 qtrs —
66 MAN GROUP PLC 64.5K +64.5K (+100.0%) 890.3K +890.3K (+100.0%) 0.10% +0.104 pp 0.00% +0.002 pp USD13.80 +0.0% 1 qtrs NEW
67 PROFUND ADVISORS LLC 64.0K +47.6K (+289.5%) 883.5K +481.8K (+119.9%) 0.10% +0.077 pp 0.03% +0.014 pp USD18.95 -27.2% 7 qtrs —
68 HRT FINANCIAL LP 63.5K +63.5K (+100.0%) 876.0K +876.0K (+100.0%) 0.10% +0.103 pp 0.00% +0.003 pp USD13.80 +0.0% 1 qtrs NEW
69 TWINBEECH CAPITAL LP 58.8K +58.8K (+100.0%) 811.6K +811.6K (+100.0%) 0.09% +0.095 pp 0.06% +0.058 pp USD13.80 +0.0% 4 qtrs —
70 DARK FOREST CAPITAL MANAGEMENT LP 57.4K +33.7K (+142.6%) 791.6K +213.7K (+37.0%) 0.09% +0.054 pp 0.04% +0.019 pp USD19.17 -28.0% 4 qtrs —
71 CONGRESS ASSET MANAGEMENT CO /MA 57.3K +1.6K (+2.8%) 791.3K -571.8K (-41.9%) 0.09% +0.002 pp 0.01% -0.004 pp USD24.15 -42.9% 2 qtrs —
72 HEADLANDS TECHNOLOGIES LLC 56.5K +56.5K (+100.0%) 779.7K +779.7K (+100.0%) 0.09% +0.091 pp 0.07% +0.065 pp USD13.80 +0.0% 1 qtrs NEW
73 AQUATIC CAPITAL MANAGEMENT LLC 52.4K +52.4K (+100.0%) 723.4K +723.4K (+100.0%) 0.08% +0.085 pp 0.02% +0.021 pp USD13.80 +0.0% 5 qtrs —
74 RHUMBLINE ADVISERS 52.4K -5.3K (-9.2%) 722.6K -686.2K (-48.7%) 0.08% -0.009 pp 0.00% -0.001 pp USD24.51 -43.7% 18 qtrs —
75 WELLS FARGO & COMPANY/MN 47.9K +19.4K (+68.0%) 661.3K -35.7K (-5.1%) 0.08% +0.031 pp 0.00% +0.000 pp USD22.67 -39.1% 18 qtrs —
76 RAIFFEISEN BANK INTERNATIONAL AG 46.0K +22.0K (+91.7%) 636.2K +67.4K (+11.8%) 0.07% +0.035 pp 0.01% +0.001 pp USD19.35 -28.7% 2 qtrs —
77 SCHONFELD STRATEGIC ADVISORS LLC 45.5K +45.5K (+100.0%) 627.3K +627.3K (+100.0%) 0.07% +0.073 pp 0.00% +0.003 pp USD13.80 +0.0% 1 qtrs NEW
78 LEGAL & GENERAL GROUP PLC 43.5K +5.6K (+14.6%) 599.8K -326.8K (-35.3%) 0.07% +0.009 pp 0.00% 0.000 pp USD31.42 -56.1% 18 qtrs —
79 FREESTONE GROVE PARTNERS LP 41.8K +41.8K (+100.0%) 576.9K +576.9K (+100.0%) 0.07% +0.067 pp 0.00% +0.004 pp USD13.80 +0.0% 1 qtrs NEW
80 HIGHVISTA STRATEGIES LLC 41.4K -13.8K (-25.0%) 571.9K -778.4K (-57.6%) 0.07% -0.022 pp 0.15% -0.184 pp USD48.10 -71.3% 7 qtrs —
81 TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY 38.9K +38.9K (+100.0%) 536.0K +536.0K (+100.0%) 0.06% +0.063 pp 0.00% +0.004 pp USD13.80 +0.0% 1 qtrs NEW
82 STATE OF WISCONSIN INVESTMENT BOARD 38.5K +5.0K (+14.8%) 531.1K -288.1K (-35.2%) 0.06% +0.008 pp 0.00% -0.001 pp USD27.00 -48.9% 12 qtrs —
83 NEOS INVESTMENT MANAGEMENT LLC 37.6K -2.7K (-6.7%) 519.5K -466.6K (-47.3%) 0.06% -0.005 pp 0.00% -0.004 pp USD28.32 -51.3% 7 qtrs —
84 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 37.3K +173.0 (+0.5%) 515.0K -392.9K (-43.3%) 0.06% +0.000 pp 0.00% 0.000 pp USD35.10 -60.7% 18 qtrs —
85 TEMA ETFS LLC 37.1K -3.3K (-8.1%) 511.9K -474.3K (-48.1%) 0.06% -0.005 pp 0.04% -0.042 pp USD29.45 -53.1% 5 qtrs —
86 MANUFACTURERS LIFE INSURANCE COMPANY, THE 36.6K -28.4K (-43.8%) 505.0K -1.1M (-68.2%) 0.06% -0.046 pp 0.00% -0.001 pp USD44.34 -68.9% 8 qtrs —
87 ALLIANCEBERNSTEIN L.P. 35.6K +— (+0.0%) 491.1K -378.7K (-43.5%) 0.06% 0.000 pp 0.00% 0.000 pp USD25.14 -45.1% 11 qtrs —
88 QUADRATURE CAPITAL LTD 33.0K +6.1K (+22.9%) 455.4K -201.1K (-30.6%) 0.05% +0.010 pp 0.00% -0.003 pp USD22.46 -38.6% 2 qtrs —
89 D. E. SHAW & CO., INC. 32.7K +32.7K (+100.0%) 451.4K +451.4K (+100.0%) 0.05% +0.053 pp 0.00% +0.000 pp USD13.80 +0.0% 1 qtrs NEW
90 DEUTSCHE BANK AG\ 32.2K -4.0K (-11.0%) 443.9K -439.8K (-49.8%) 0.05% -0.007 pp 0.00% 0.000 pp USD44.14 -68.7% 18 qtrs —
91 WINTON GROUP LTD 31.8K +31.8K (+100.0%) 438.8K +438.8K (+100.0%) 0.05% +0.051 pp 0.02% +0.015 pp USD13.80 +0.0% 1 qtrs NEW
92 MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. 30.1K +7.8K (+34.8%) 416.3K -127.3K (-23.4%) 0.05% +0.013 pp 0.00% 0.000 pp USD32.34 -57.3% 7 qtrs —
93 DIADEMA PARTNERS LP 30.0K +30.0K (+100.0%) 414.0K +414.0K (+100.0%) 0.05% +0.048 pp 0.07% +0.071 pp USD13.80 +0.0% 1 qtrs NEW
94 INVESCO LTD. 28.3K +3.9K (+15.7%) 390.8K -207.2K (-34.6%) 0.05% +0.006 pp 0.00% +0.000 pp USD41.46 -66.7% 8 qtrs —
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 91 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares Genomics Immunology and Healthcare ETF IDNA 1.03% 2.02M 0.47%
2 Federated Hermes MDT Small Cap Core ETF FSCC 0.85% 1.40M 0.51%
3 Virtus Biotech Clinical Trials ETF BBC 0.74% 428.5K 0.65%
4 Tema Oncology ETF CANC 0.44% 624.8K 0.75%
5 Fidelity Disruptive Medicine ETF FMED 0.40% 186.6K 0.50%
6 Global X - S&P Biotech ETF CURE.AX 0.29% 105.6K 0.45%
7 State Street SPDR S&P Biotech ETF XBI 0.29% 31.71M 0.35%
8 Innovator U.S. Small Cap Managed Floor ETF RFLR 0.11% 96.8K 0.89%
9 iShares Healthcare Innovation UCITS ETF HEAL.L 0.09% 1.04M 0.40%
10 iShares Biotechnology ETF IBB 0.07% 6.74M 0.44%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
2.33
Bullish
Ratio by volume
3.00
Bullish
Buys
14
Sells
6
Shares acquired
1.26M
Shares disposed
19.0K
Cash buys
—
Cash sales
6.00
Net activity
+1,237,702
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-02-02 Go William Officer A-Award A Stock option (right to buy) 154,000 13.99 2.15M 154,000 D ↗
2026-01-26 Go William — — — — 0 0.00 — 0 — ↗
2026-01-02 Winter Charles M. Officer A-Award A Stock option (right to buy) 100,100 13.65 1.37M 100,100 D ↗
2026-01-02 Meyer Andrew Hollman Officer S-Sale D Common Stock 1,879 13.73 25.8K 83,095 D ↗
2026-01-02 McIver Zachariah Officer S-Sale D Common Stock 2,714 13.73 37.3K 23,286 D ↗
2026-01-02 Doyle Janeen Noel Officer A-Award A Common Stock 36,000 0.00 — 80,000 D ↗
2026-01-02 Dobek Maria Officer S-Sale D Common Stock 1,462 13.73 20.1K 15,373 D ↗
2026-01-02 DiRaimondo Thomas Officer A-Award A Stock option (right to buy) 109,900 13.65 1.50M 109,900 D ↗
2026-01-02 Campbell David Alan Director / Officer S-Sale D Common Stock 8,072 13.73 110.8K 284,982 D ↗
2025-12-01 Meyer Andrew Hollman Officer M-Exempt D Stock Option (right to buy) 3,333 10.59 35.3K 114,768 D ↗
2025-11-14 Meyer Andrew Hollman Officer M-Exempt A Common Stock 3,333 10.59 35.3K 88,307 D ↗
2025-10-28 Meyer Andrew Hollman Officer M-Exempt A Common Stock 6,666 10.59 70.6K 98,804 D ↗
2025-06-11 Simson Jake Director A-Award A Common Stock 3,750 0.00 — 6,250 D ↗
2025-06-11 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner A-Award A Common Stock 3,750 0.00 — 6,250 I ↗
2025-06-11 McNulty Alana B. Director A-Award A Common Stock 3,750 0.00 — 6,250 D ↗
2025-06-11 Kung Winston Director A-Award A Stock Option (right to buy) 11,667 25.46 297.0K 11,667 D ↗
2025-06-11 Hernday Natasha Director A-Award A Common Stock 3,750 0.00 — 8,731 D ↗
2025-06-11 Gujrathi Sheila Director A-Award A Stock Option (right to buy) 11,667 25.46 297.0K 11,667 D ↗
2025-06-11 DOBMEIER ERIC Director A-Award A Stock Option (right to buy) 11,667 25.46 297.0K 11,667 D ↗
2025-06-11 CAPPS VICKIE L Director A-Award A Stock Option (right to buy) 11,667 25.46 297.0K 11,667 D ↗
2025-06-11 Barrett Ronald W Director A-Award A Common Stock 3,750 0.00 — 6,250 D ↗
2025-06-02 Doyle Janeen Noel Officer A-Award A Stock option (right to buy) 154,000 25.01 3.85M 154,000 D ↗
2025-05-14 Doyle Janeen Noel — — — — 0 0.00 — 0 — ↗
2025-05-01 Meyer Andrew Hollman Officer M-Exempt D Stock Option (right to buy) 3,333 4.21 14.0K 87,332 D ↗
2025-04-21 Meyer Andrew Hollman Officer M-Exempt D Stock Option (right to buy) 3,334 4.21 14.0K 90,665 D ↗
2025-03-07 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Common Stock 110,206 31.02 3.42M 10,141,287 I ↗
2025-03-06 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Common Stock 372,093 30.78 11.45M 10,031,081 I ↗
2025-03-05 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Common Stock 37,455 31.30 1.17M 9,658,988 I ↗
2025-03-03 Meyer Andrew Hollman Officer M-Exempt A Common Stock 3,334 4.21 14.0K 85,473 D ↗
2025-02-03 Meyer Andrew Hollman Officer M-Exempt D Stock Option (right to buy) 3,334 4.21 14.0K 97,333 D ↗
2025-01-07 Campbell David Alan Director / Officer S-Sale D Common Stock 5,000 60.00 300.0K 293,054 D ↗
2025-01-02 Winter Charles M. Officer A-Award A Common Stock 23,000 0.00 — 77,288 D ↗
2025-01-02 Robinson Byron Officer A-Award A Stock option (right to buy) 98,000 53.24 5.22M 98,000 D ↗
2025-01-02 Meyer Andrew Hollman Officer S-Sale D Common Stock 3,444 55.76 192.0K 83,339 D ↗
2025-01-02 McIver Zachariah Officer A-Award A Stock option (right to buy) 91,000 53.24 4.84M 91,000 D ↗
2025-01-02 Dobek Maria Officer A-Award A Stock option (right to buy) 31,500 53.24 1.68M 31,500 D ↗
2025-01-02 DiRaimondo Thomas Officer A-Award A Stock option (right to buy) 84,000 53.24 4.47M 84,000 D ↗
2025-01-02 Campbell David Alan Director / Officer A-Award A Common Stock 81,000 0.00 — 298,054 D ↗
2025-01-01 McIver Zachariah Officer — — Stock option (right to buy) 62,500 12.10 756.3K 0 D ↗
2024-12-24 Campbell David Alan Director / Officer S-Sale D Common Stock 25,000 56.19 1.40M 217,054 D ↗
2024-12-19 Meyer Andrew Hollman Officer M-Exempt D Stock Option (right to buy) 9,880 20.24 200.0K 96,870 D ↗
2024-12-03 Campbell David Alan Director / Officer S-Sale D Common Stock 15,000 67.00 1.01M 242,054 D ↗
2024-11-25 Campbell David Alan Director / Officer S-Sale D Common Stock 18,281 51.43 940.2K 263,773 D ↗
2024-11-05 Gujrathi Sheila Director J-Other A Common Stock 4,611 0.00 — 115,139 D ↗
2024-11-05 CAPPS VICKIE L Director J-Other A Common Stock 2,305 0.00 — 70,348 D ↗
2024-10-28 Campbell David Alan Director / Officer S-Sale D Common Stock 13,897 53.22 739.6K 293,157 D ↗
2024-10-18 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Common Stock 1,200,000 44.75 53.70M 9,317,246 I ↗
2024-10-18 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 104,957 44.75 4.70M 401,321 I ↗
2024-10-17 Avalon Ventures XI, L.P. 10% Owner M-Exempt D Stock Option (right to buy) 836 17.00 14.2K 21,940 D ↗
2024-10-16 Avalon Ventures XI, L.P. 10% Owner M-Exempt A Common Stock 4,968 17.00 84.5K 11,855 D ↗
2024-09-30 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 958 46.24 44.3K 6,887 D ↗
2024-09-27 Meyer Andrew Hollman Officer M-Exempt A Common Stock 50,000 4.21 210.5K 117,592 D ↗
2024-09-27 DiRaimondo Thomas Officer S-Sale D Common Stock 675 47.22 31.9K 97,938 D ↗
2024-09-27 Campbell David Alan Director / Officer S-Sale D Common Stock 795 47.84 38.0K 307,054 D ↗
2024-09-27 Avalon Ventures XI, L.P. 10% Owner M-Exempt D Stock Option (right to buy) 234 39.80 9.3K 7,839 D ↗
2024-09-26 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 9,592 46.78 448.7K 563,635 I ↗
2024-09-13 Lichter Jay 10% Owner M-Exempt A Common Stock 778 10.73 8.3K 9,646 D ↗
2024-09-12 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 161,356 47.00 7.58M 3,021,414 — ↗
2024-09-10 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 6,649 46.66 310.2K 603,840 — ↗
2024-09-09 Avalon Ventures XI, L.P. 10% Owner M-Exempt A Common Stock 277 39.80 11.0K 9,182 — ↗
2024-09-06 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 20,991 42.00 881.6K 612,682 — ↗
2024-08-08 Dobek Maria Officer — D Stock option (right to buy) 4,337 10.59 45.9K 0 — ↗
2024-07-19 Hernday Natasha Director A-Award A Common Stock 5,000 0.00 — 5,000 — ↗
2024-07-19 DOBMEIER ERIC Director A-Award A Stock Option (Right to Buy) 4,111 44.68 183.7K 4,111 — ↗
2024-06-26 Simson Jake Director A-Award A Stock Option (right to buy) 8,350 39.80 332.3K 8,350 — ↗
2024-06-26 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner A-Award A Common Stock 2,500 0.00 — 2,500 — ↗
2024-06-26 McNulty Alana B. Director A-Award A Stock Option (right to buy) 8,350 39.80 332.3K 8,350 — ↗
2024-06-26 Lichter Jay Director / 10% Owner A-Award A Common Stock 2,500 0.00 — 7,083 — ↗
2024-06-26 Kung Winston Director A-Award A Common Stock 2,500 0.00 — 2,500 — ↗
2024-06-26 Gujrathi Sheila Director A-Award A Stock Option (right to buy) 8,350 39.80 332.3K 8,350 — ↗
2024-06-26 CAPPS VICKIE L Director A-Award A Common Stock 2,500 0.00 — 68,043 — ↗
2024-06-26 Barrett Ronald W Director A-Award A Stock Option (right to buy) 8,350 39.80 332.3K 8,350 — ↗
2024-06-03 Reardon Tighe Officer S-Sale D Common Stock 691,525 54.75 37.86M 3,340,018 — ↗
2024-06-03 Lichter Jay Director / 10% Owner S-Sale D Common Stock 131,196 54.75 7.18M 633,673 — ↗
2024-06-03 Avalon Ventures XI, L.P. 10% Owner S-Sale D Common Stock 131,196 54.75 7.18M 633,673 — ↗
2024-03-04 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Pre-Funded Warrants (Right to Buy) 1,397,849 0.00 1.4K 1,397,849 — ↗
2024-02-29 Gujrathi Sheila Director J-Other A Common Stock 2,986 0.00 — 108,028 — ↗
2024-02-29 CAPPS VICKIE L Director J-Other A Common Stock 1,493 0.00 — 65,543 — ↗
2024-02-29 Avalon Ventures XI, L.P. 10% Owner J-Other D Common Stock 447,949 0.00 — 4,031,543 — ↗
2024-01-02 Winter Charles M. Officer A-Award A Stock Option (right to buy) 111,000 11.02 1.22M 111,000 — ↗
2024-01-02 Robinson Byron Officer A-Award A Stock Option (right to buy) 151,500 11.02 1.67M 151,500 — ↗
2024-01-02 Reardon Tighe Officer / 10% Owner A-Award A Stock Option (right to buy) 157,000 11.02 1.73M 157,000 — ↗
2024-01-02 Meyer Andrew Hollman Officer A-Award A Stock Option (right to buy) 105,000 11.02 1.16M 105,000 — ↗
2024-01-02 DiRaimondo Thomas Officer A-Award A Stock Option (right to buy) 147,000 11.02 1.62M 147,000 — ↗
2024-01-02 Campbell David Alan Director / Officer A-Award A Stock Option (right to buy) 356,500 11.02 3.93M 356,500 — ↗
2024-01-01 DiRaimondo Thomas Officer — D Stock option (right to buy) 70,000 14.02 981.4K 0 — ↗
2023-11-13 Reardon Tighe Officer / 10% Owner P-Purchase A Common Stock 849,854 5.87 4.99M 849,854 — ↗
2023-11-13 Lichter Jay Director / 10% Owner P-Purchase A Common Stock 849,854 5.87 4.99M 849,854 — ↗
2023-11-13 Avalon Ventures XI, L.P. 10% Owner P-Purchase A Common Stock 849,854 5.87 4.99M 849,854 — ↗
2023-07-19 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Common Stock 495,008 12.46 6.17M 8,117,246 — ↗
2023-06-14 Simson Jake Director A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner A-Award A Stock Option (Right to Buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 McNulty Alana B. Director A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 Lichter Jay Director / 10% Owner A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 Kung Winston Director A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 Gujrathi Sheila Director A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 CAPPS VICKIE L Director A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-06-14 Barrett Ronald W Director A-Award A Stock Option (right to buy) 12,500 13.22 165.3K 12,500 — ↗
2023-01-03 Winter Charles M. Officer A-Award A Stock Option (right to buy) 100,000 0.00 — 100,000 — ↗
2023-01-03 Robinson Byron Officer A-Award A Stock Option (right to buy) 100,000 0.00 — 100,000 — ↗
2023-01-03 Reardon Tighe Officer A-Award A Stock Option (right to buy) 110,000 0.00 — 110,000 — ↗
2023-01-03 Meyer Andrew Hollman Officer A-Award A Stock Option (right to buy) 90,000 0.00 — 90,000 — ↗
2023-01-03 Godfrey Wayne Officer A-Award A Stock Option (right to buy) 110,000 0.00 — 110,000 — ↗
2023-01-03 Campbell David Alan Officer A-Award A Stock Option (right to buy) 310,000 0.00 — 310,000 — ↗
2023-01-01 Winter Charles M. Officer — — Common Stock 0 0.00 — 46,111 D ↗
2022-09-21 Kung Winston Director A-Award A Stock Option (right to buy) 30,000 13.54 406.2K 30,000 — ↗
2022-06-14 Thompson Peter A. Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 Simson Jake Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 Shah Rajeev M. Director A-Award A Stock Option (Right to Buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner A-Award A Stock Option (Right to Buy) 12,500 10.73 134.1K 12,500 — ↗
2022-06-14 McNulty Alana B. Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 Lichter Jay Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 Heller Stefan Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 Gujrathi Sheila Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 CAPPS VICKIE L Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-06-14 Barrett Ronald W Director A-Award A Stock Option (right to buy) 12,500 0.00 — 12,500 — ↗
2022-03-01 Robinson Byron Officer A-Award A Stock Option (right to buy) 230,000 0.00 — 230,000 — ↗
2022-01-03 Salek-Ardakani Shahram Officer A-Award A Stock Option (right to buy) 114,250 20.24 2.31M 114,250 — ↗
2022-01-03 Reardon Tighe Officer / 10% Owner A-Award A Stock Option (right to buy) 116,750 20.24 2.36M 116,750 — ↗
2022-01-03 Meyer Andrew Hollman Officer A-Award A Stock Option (right to buy) 106,750 20.24 2.16M 106,750 — ↗
2022-01-03 Godfrey Wayne Officer A-Award A Stock Option (right to buy) 114,250 20.24 2.31M 114,250 — ↗
2022-01-03 Campbell David Alan Director / Officer A-Award A Stock Option (right to buy) 354,250 20.24 7.17M 354,250 — ↗
2021-12-29 Thompson Peter A. Director S-Sale D Common Stock 36,700 20.30 745.0K 2,258,566 — ↗
2021-12-29 ORBIMED ADVISORS LLC Director S-Sale D Common Stock 36,700 20.30 745.0K 2,258,566 — ↗
2021-12-21 Thompson Peter A. Director S-Sale D Common Stock 11,100 19.00 210.9K 234,798 — ↗
2021-12-21 ORBIMED ADVISORS LLC Director S-Sale D Common Stock 11,100 19.00 210.9K 234,798 — ↗
2021-12-16 Thompson Peter A. Director S-Sale D Common Stock 356,800 19.07 6.80M 2,403,566 — ↗
2021-12-16 ORBIMED ADVISORS LLC Director S-Sale D Common Stock 356,800 19.07 6.80M 2,403,566 — ↗
2021-09-07 McNulty Alana B. Director A-Award A Stock Option (right to buy) 30,000 29.58 887.4K 30,000 — ↗
2021-09-07 Barrett Ronald W Director A-Award A Stock Option (right to buy) 30,000 29.58 887.4K 30,000 — ↗
2021-07-12 Salek-Ardakani Shahram Officer — D Stock Option (right to buy) 416,325 10.59 4.41M 0 — ↗
2021-06-15 Thompson Peter A. Director P-Purchase A Common Stock 117,650 17.00 2.00M 282,398 — ↗
2021-06-15 Reardon Tighe Officer / 10% Owner C-Conversion D Series A Convertible Preferred Stock 2,105,264 0.00 — 0 — ↗
2021-06-15 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner P-Purchase A Common Stock 2,752,190 17.00 46.79M 7,622,238 — ↗
2021-06-15 ORBIMED ADVISORS LLC Director P-Purchase A Common Stock 117,650 17.00 2.00M 282,398 — ↗
2021-06-15 Lichter Jay Director / 10% Owner C-Conversion D Series Seed 2 Convertible Preferred Stock 1,859,634 0.00 — 0 — ↗
2021-06-15 Bregua Corp 10% Owner P-Purchase A Common Stock 58,823 17.00 1,000.0K 3,749,250 — ↗
2021-06-15 Avalon Ventures XI, L.P. 10% Owner C-Conversion A Common Stock 674,211 0.00 — 4,387,217 — ↗
2021-06-10 Thompson Peter A. Director / 10% Owner A-Award A Stock Option (right to buy) 30,000 17.00 510.0K 30,000 — ↗
2021-06-10 Simson Jake Director A-Award A Stock Option (right to buy) 30,000 17.00 510.0K 30,000 — ↗
2021-06-10 Reardon Tighe Officer / 10% Owner — I Series A Convertible Preferred Stock 2,696,843 0.00 — 0 — ↗
2021-06-10 RA CAPITAL MANAGEMENT, L.P. Director / 10% Owner — I Series B Convertible Preferred Stock 556,026 0.00 — 0 — ↗
2021-06-10 ORBIMED ADVISORS LLC Director — I Series A Convertible Preferred Stock 1,348,421 0.00 — 0 — ↗
2021-06-10 Meyer Andrew Hollman Officer — D Common Stock 0 0.00 — 59,416 — ↗
2021-06-10 Lichter Jay Director / 10% Owner — I Common Stock 0 0.00 — 192,150 — ↗
2021-06-10 Heller Stefan Director — D Common Stock 0 0.00 — 96,075 — ↗
2021-06-10 Gujrathi Sheila Director — D Common Stock 0 0.00 — 105,042 — ↗
2021-06-10 Godfrey Wayne Officer — D Stock Option (right to buy) 448,350 10.59 4.75M 0 — ↗
2021-06-10 Campbell David Alan Director / Officer — D Common Stock 0 0.00 — 332,054 — ↗
2021-06-10 CAPPS VICKIE L Director — D Stock Option (right to buy) 32,025 10.59 339.0K 0 — ↗
2021-06-10 Bregua Corp 10% Owner — D Series A Convertible Preferred Stock 674,211 0.00 — 0 — ↗
2021-06-10 Avalon Ventures XI, L.P. 10% Owner — D Common Stock 0 0.00 — 192,150 — ↗

Executive team

Top executives
EBIT / Employee
-12.5K
Shares Outstanding
60.98M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2023 David Campbell, Ph.D. President and Chief Executive Officer 625.0K — — 3.16M 412.5K — 4.19M 75.26% ↗
2 2023 Byron Robinson, Ph.D., J.D. Chief Strategic Officer 450.0K 75.0K — 1.02M 198.0K — 1.74M 58.47% ↗
3 2023 Charles Winter Chief Technical Officer 410.0K — — 1.02M 180.4K — 1.61M 63.29% ↗
4 2022 David Campbell, Ph.D. President and Chief Executive Officer 550.0K — — 5.15M 302.5K — 6.00M 85.80% ↗
5 2022 Byron Robinson, Ph.D., J.D. Chief Strategic Officer 351.9K 100.0K — 2.76M 154.9K — 3.37M 81.98% ↗
6 2022 Byron Robinson, Ph.D., J.D. Chief Strategy Officer 351.9K 100.0K — 2.76M 154.9K — 3.37M 81.98% ↗
7 2022 Wayne Godfrey, M.D. Chief Medical Officer 435.0K — — 1.66M 191.4K — 2.29M 72.61% ↗
8 2022 Charles Winter Chief Technical Officer 315.0K — — 1.13M 104.0K — 1.55M 73.02% ↗
9 2021 David Campbell, Ph.D. President and Chief Executive Officer 459.1K — — 7.72M 229.5K — 8.41M 91.81% ↗
10 2021 Wayne Godfrey, M.D. Chief Medical Officer 257.0K — — 3.92M 102.8K — 4.28M 91.59% ↗
11 2021 Shahram Salek-Ardakani, Ph.D. Chief Scientific Officer 189.4K 125.0K — 3.64M 56.8K — 4.01M 90.74% ↗
12 2020 David Campbell, Ph.D. President and Chief Executive Officer 405.1K 141.8K — 225.9K — 38.9K 811.7K 27.83% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-04-28 DEFA14A ↗
2026-04-28 DEF 14A ↗
2025-04-25 DEFA14A ↗
2025-04-25 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-07 8-K ↗
2026-05-07 10-Q ↗
2026-05-06 SC 13G/A ↗
2026-04-29 SC 13G ↗
2026-04-29 SC 13G ↗
2026-04-28 DEFA14A ↗
2026-04-28 DEF 14A ↗
2026-04-28 ARS ↗
2026-04-28 8-K ↗
2026-02-26 S-8 ↗

Executive team

NameTitleCompensationGender
David Alan Campbell President, Co-Founder, CEO & Director 1M —
Thomas Diraimondo Chief Scientific Officer 653.9K —
William Y. Go Chief Medical Officer 626.4K —
Charles Winter Chief Technical Officer 590.4K male
Janeen Doyle Chief Corporate & Business Development Officer 549.0K female
Maria Dobek Vice President of Accounting — female
Matt Whitmire Vice President of Finance — male
James Pennington General Counsel & Corporate Secretary — male
ESG Rating
B
BIOTECHNOLOGY
2026
E (Environmental)
62.9 / 56.3
Company / Sector avg.
S (Social)
62.5 / 62.4
Company / Sector avg.
G (Governance)
57.5 / 60.9
Company / Sector avg.
ESG Total
61.0 / 59.9
Company / Sector avg.
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology